Clinical Trial Detail

NCT ID NCT02272686
Title Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

B-cell lymphoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.